Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation.

The introduction cites the iKMC trial and the Gambia eKMC trial, notes their limitations (underpowering, lack of economic data, sub-Saharan Africa focus), and explains why the OMWaNA trial is needed. The rationale for comparing KMC before stabilisation vs standard care is clearly linked to the evidence gap and WHO guideline changes. The limitations of previous work are acknowledged and addressed by the study design and embedded economic evaluation.

The study is an individually randomised parallel-group trial with computer-generated random allocation, permuted blocks of varying sizes, stratification by birthweight and site, and allocation concealment via the REDCap database. The independent statistician was masked; parents and staff were not, which is expected given the intervention. A priori sample size calculation is provided (2188 neonates, 80% power, 5% significance, 20% attrition). Inclusion and exclusion criteria are clearly described. The primary analysis is intention-to-treat. The paper explicitly states the trial was conducted in accordance with CONSORT guidelines. All applicable sub-criteria are adequately reported.

Table 1 shows baseline characteristics for both groups, including birthweight, gestational age, sex, mode of delivery, birth location, and multiple-birth status. Mothers' age, education, and monthly income are reported. Sex is reported with both sexes enrolled, so a single-sex justification is not needed. Age and weight at screening are reported. Species/strain and housing conditions are not applicable for a human trial. Demographics are reported in adequate detail.

The paper states that the study was approved by the Research Ethics Committees of Uganda Virus Research Institute (GC/127/19/06/717), Uganda National Council of Science and Technology (HS 2645), and London School of Hygiene & Tropical Medicine (16972). Written informed consent is described. The trial is reported in accordance with CONSORT and CHEERS guidelines, and the study was overseen by a steering committee and independent DSMB. This meets the criteria for adequate ethics reporting.

The study evaluates a care practice (kangaroo mother care), not a pharmacological or biological agent. Key software tools (REDCap, Stata 18.1, Microsoft Excel) are identified with versions. No antibodies, cell lines, mycoplasma testing, or organisms other than human neonates apply. The trial does not use a drug, biologic, or device as an investigational product, so reagents_identified is not applicable; the intervention and control procedures are adequately described. Software_tools_identified is adequate.

All statistical tests are named (modified Poisson regression, Cox proportional hazards, linear regression) with robust SEs. Exact p-values and 95% CIs are reported for primary and secondary outcomes. Effect sizes (RR, HR, mean differences) are reported with CIs. Software is identified (Stata 18.1, Excel). Data presentation includes forest plots and Kaplan-Meier curves; per-group n is clearly stated. Given the large sample and pre-specified analysis model, explicit normality testing is not required; the use of robust SEs and modified Poisson (which handles non-convergence) addresses key assumptions. Mathematical plausibility is not independently verifiable from the summary data, as means of continuous variables are reported; no arithmetic inconsistencies are evident.

The paper states: 'Data from the study will be deposited online at LSHTM Data Compass, with access subject to approval.' This is a concrete repository (LSHTM Data Compass) but with access subject to approval, which is a form of managed access. It is not a fully open dataset. No accession number is provided. Custom code sharing is not mentioned. Because the data availability statement promises deposition but the access is restricted, and code is not shared, the applicable criteria are partially met.

The methods section is comprehensive, describing participant selection, randomisation, intervention details, outcome definitions, statistical methods, and economic analysis. The trial is registered. CONSORT and CHEERS checklists were submitted (supplementary). All pre-specified outcomes from the protocol are reported in the results, including non-significant ones. Limitations are discussed in detail (sample size assumptions, unmasking, missing data, site variation). Conclusions are proportional: the authors do not claim effectiveness on the primary outcome but note benefits in secondary outcomes and cost-effectiveness. Funding sources and a conflicts-of-interest statement are provided.